Press Room


    Press Release - May 09, 2007

    Sernova Raises $2.4 Million to Advance Sertolin to Clinical Trails

    -Completes Acquisition of All Rights to Sertoli Technology-

    Kelowna, British Columbia - May 9, 2007 - Sernova Corp. (TSX-V: SVA), a company focused on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology, announced that it has raised $2.4 million through the exercise of all outstanding warrants. The funds will be used to continue the Company's development of Sertolin, Sernova's cellular therapy for diabetes.

    "The warrant exercise was an ideal way for us to raise capital for the Sertolin project without diluting our current share structure," said CEO Justin Leushner. "The company appreciates the continued support by its shareholders."

    Under the terms of the warrant agreement, the Company had a right to trigger the exercise of the warrants when the 10 day average of the closing price of the Company's shares was equal to or above $1.00 per share. With this condition met, Sernova notified warrant holders that they had until May 7, 2007 to complete the exercise of the warrants. All 4,036,375 outstanding warrants were exercised at $0.60 per share.

    Sernova also announced that it now has sole control of the Sertolin technology. With the proceeds from the exercise of the warrants, Sernova has met its financing commitments for the Sertolin technology and will complete its obligations under the original financing agreement to issue an additional 2,315,000 escrow shares. (See the Company's news release dated May 25, 2006.) Sernova has also made a cash payment of $1,142,312 to Sertoli Technologies Inc. for the exclusive license to the Sertoli cells patents. There are no further payments required under the license agreement, except for a continuing obligation to pay a small royalty on future commercial sales of products based upon the use of Sertoli cells.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin are estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact:

    TEL: (888) 318-7062 FAX: (250) 868-8493

    Phil Morehouse Sernova Corp.



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News